Skip to main content

Pharma News

 

Clinical courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • GSK's Gonorrhoea medicine shows positive results in trials

    GSK plc announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults. The trial met its primary efficacy endpoint, with gepotidacin (oral, two doses of 3,000mg) demonstrating non-inferiority to intramuscular (IM) ceftriaxone (500mg) plus oral azithromycin (1,000mg), a leading combination treatment regimen for gonorrhoea.

  • Piramal Pharma Lexington facility gets 2 USFDA observations

    US FDA conducted a Pre-Approval Inspection (PAI) inspection of Piramal Pharma Limited's Lexington (USA) facility from 20 th February, 2024 to 23rd February, 2024 for one of the product expected to be manufactured at this facility.

    On conclusion of the inspection, a Form-483 was issued with 2 observations. The observations does not pose any risk to site’s compliance standards or its business continuity.

  • Sclerosis medicine from Biogen backed by EU

    Biogen Inc announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

  • First Indian discovered antibiotic gets FDA approval, took 16 years to reach market

    Orchid Pharma, based in Chennai, India, has received approval by the United States Food and Drug Administration (USFDA) for its novel invention, ‘Enmetazobactam’. This development comes in close succession to the recent recommendation for approval by the European Medicines Agency (EMA). Enmetazobactam is the first completely invented-in-India Beta Lactamase Inhibitor.

  • Researchers are using RNA in a new approach to fight HIV

    Society learned about the value of mRNA during the COVID-19 pandemic when we saw scientists and medical professionals harness its power to deliver a vaccine for the virus within a year.

  • Research Shows Possible Risks of Too Much Niacin

    For years, vitamin B3, better known as niacin, has been added to many of the foods we eat every day.

  • 275 Million New Genetic Variants Identified in NIH Precision Medicine Data

    Researchers have discovered more than 275 million previously unreported genetic variants, identified from data shared by nearly 250,000 participants of the National Institutes of Health’s All of Us Research Program. Half of the genomic data are from participants of non-European genetic ancestry. The unexplored cache of variants provides researchers new pathways to better understand the genetic influences on health and disease, especially in communities who have been left out of research in the past.

  • Study Finds New Inhalable Therapy is a Big Step Forward in Lung Cancer Research

    Lung cancer is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines, which are small signaling proteins, such as interleukin-12 (IL-12), have demonstrated considerable potential as robust tumor suppressors. However, their applications are limited due to a multitude of severe side effects.

  • New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial

    The phase 3 clinical trial, published today in JAMA Oncology and sponsored by Polaris Pharmaceuticals, has unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with exposure to asbestos and which has limited therapeutic options. The trial found that a combination treatment of traditional chemotherapy with a new drug, ADI-PEG20, increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy.

  • Treating liver cancer with microrobots piloted by a magnetic field

    Canadian researchers led by Montreal radiologist Gilles Soulez have developed a novel approach to treat liver tumours using magnet-guided microrobots in an MRI device.

    The idea of injecting microscopic robots into the bloodstream to heal the human body is not new. It’s also not science fiction.

Subscribe to Pharma News